Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Researchers genetically engineer snake antivenom

An international team of researchers has used genetic engineering to create so-called...

Common medications linked to adverse breast cancer outcomes

An international study has found concerning evidence about the impact of a range of common...

Saliva-based biosensor could improve heart failure detection

Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...

Content from other channels on our network

ARC announces $34m in collaborative research funding

Brisbane biomanufacturing hub signs its first tenant

Carbon280 seeks further funding for Hydrilyte technology

Highly precise and safe control of hydrogen testing

Victoria supporting a new mRNA manufacturing facility

Some patients wait 6 years to see a public hospital specialist. Here's how to fix this

19th Victorian Public Healthcare Awards — winners revealed

Remote laundries target preventable disease in NT communities

UNSW Health Translation Hub opens

UNSW Health Translation Hub

Deal to create graphene-based carbon paste used in solar

Net zero or 1.2 million homes: trade-off or win-win?

Mining waste provides strong boost to concrete construction

Alta project makes existing diesel trains electric

Australia signs declaration to transition from fossil fuels